Development of Insulin Resistance through Induction

of miRNA-135 in C2C12 Cells by Honardoost, Maryam et al.
CELL JOURNAL(Yakhteh), Vol 18, No 3, Oct-Dec (Autumn) 2016 353
Original Article
Development of Insulin Resistance through Induction
 of miRNA-135 in C2C12 Cells
Maryam Honardoost, Ph.D.1, 2, Ehsan Arefian, Ph.D.3, Masoud Soleimani, Ph.D.4, 
Sara Soudi, Ph.D.5, Mohammad Reza Sarookhani, Ph.D.1*
1. Department of Molecular Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
2. Stem Cell Technology Research Center, Tehran, Iran
3. Department of Microbiology, School of  Biology, College of  Science, University of Tehran, Tehran, Iran
4. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
5. Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
*Corresponding Address: P.O.Box: 934197-59811, Department of Molecular Medicine, School of Medicine, Qazvin
 University of Medical Sciences, Qazvin, Iran
Email: msarookhani@qums.ac.ir
 
Received: 29/Nov/2015, Accepted: 16/Sep/2016 
Abstract
Objective: Micro-RNAs (miRNAs) are a class of posttranscriptional regulators that play 
crucial roles in various biological processes. Emerging evidence suggests a direct link 
between miRNAs and development of several diseases including type 2 diabetes (T2D). 
In this study, we aimed to investigate the effect of predicted miRNA and target genes on 
insulin resistance.       
Materials and Methods: This experimental study was conducted on the C2C12 cell line. 
Using bioinformatics tools miRNA-135 and two respective target genes-insulin receptor 
(Insr) and vesicle associated membrane protein 2 (Vamp2)- were selected as potential 
factors involved in insulin resistance process. Levels of glucose uptake miRNA expression 
and respective gene targets were determined after cell transfaction by miR-135.     
Results: It was determined that Insr gene expression was significantly down-regulated 
in miR-135 transfected C2C12 cell line (P≤0.05). Interestingly; these transfected cells 
have shown a significant difference in glucose uptake incomparision the positive control 
cells, while it was similar to the insulin resistant cell line (P≤0.05). In contrast, no signifi-
cant alteration of Vamp2 gene expression was observed.                      
Conclusion: Our data indicated no change on the Vamp2 expression level after miR-
NA transfection, while expression level of Insr was reduced and miR-135 expression 
was contrarily increased leading to poor stimulation of glucose uptake through insu-
lin, and development of insulin resistance phenotype in C2C12 cell line.            
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Introduction
Micro-RNAs (miRNAs) are small noncoding 
RNA molecules composed of 21-23 nucleotides 
regulating gene expression through inhibition or 
degradation of 3´UTR of target mRNA (1). Sev-
eral evidences indicate on the pivotal roles of these 
biological molecules in a wide variety of physi-
ological processes and diseases (2-5). Thus, it is 
not surprising that the discovery of entirely new 
class of gene expression regulators prompted sev-
eral research teams to investigate the potential ef-
fect of miRNAs on the development of diabetes 
and its complications (6, 7). Now a day, growing 
evidences indicate that miRNAs are involved in 
the pathogenesis of type 2 diabetes (T2D) (7, 8).
T2D is a less defined condition, culminating in 
dysregulation of blood glucose levels due to devel-
opment of insulin resistance and/or relative insulin 
deficiency. Insulin resistance, as a major component 
of T2D disease, is thought to result mainly from the 
various environmental factors including obesity (8).
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Skeletal muscle insulin resistance is the ear-
liest visible metabolic defect during the onset 
of T2D disease (9, 10). Additionally, skeletal 
muscle insulin resistance could lead to the other 
metabolic syndrome related deregulations (11, 
12). Therefore, further understanding of skel-
etal muscle insulin resistance mechanisms is 
imperative.
Diverse mechanisms have been identified as 
underlying factors responsible for skeletal mus-
cle insulin resistance, such as genetic components 
(13, 14). Using different approaches to identify the 
genes associated with T2D, more than 30 genes 
have determined contributing to insulin resistance, 
most of which could affect insulin signaling path-
way (15).
Alternatively, detection of miRNAs, as impor-
tant metabolic regulators, have highlighted a novel 
regulatory mechanism of action suggesting a pos-
sible role of these RNA molecules in diabetes. 
Consistent with previous studies demonstrating 
contribution of very specific miRNAs in various 
metabolic processes associated to T2D, it is pro-
posed that miRNAs play critical roles during the 
inception and progression of this complex meta-
bolic disease (16-18).
Although unusual miRNA signatures have been 
reported with regards to diabetes, the status and 
role of these miRNAs have yet remained to be 
elucidated in the diabetic skeletal muscle. There-
fore, an exhaustive investigation of miRNA roles 
in the diabetic skeletal muscle is necessary (19). It 
has been demonstrated that insulin resistance was 
developed in skeletal muscle cell lines, including 
C2C12 muscle cells (20, 21). Therefore, this cell 
line could be used to screen the potential com-
pounds like miRNAs- involved in insulin resist-
ance of skeletal muscle.
In this study, we bioinformatically focused on 
miR-135 and two predicted target genes, insulin 
receptor (Insr) and vesicle associated membrane 
protein 2  (Vamp2) as the first components in the 
cascade causing insulin resistance in cells. Insu-
lin receptor signal transduction has been shown in 
Figure 1. Decrease in INSR expression has been 
described in the obese insulin resistant patients 
with T2D, as remarkably hyperinsulinemic indi-
viduals (15, 22). 
Insulin helps glucose transportation by promot-
ing the exocytosis of the glucose transporter type 
4 (GLUT4) through plasma membrane. Delivery 
of GLUT4 to the plasma membrane is mediated 
by formation of functional complexes containing 
VAMP2 that mediates cAMP-stimulated exocy-
tosis in endocrine cells. Delivery of GLUT4 has 
been indicated to be impaired in the disease states 
of insulin resistance and T2D (23).
In this study, we aimed to investigate the ef-
fect of predicted miRNA (miR-135) and two 
respective target genes in development of insu-
lin resistance. We have provided evidences that 
miR-135 directly induces insulin resistance in 
C2C12 cell line by targeting the insulin signal-
ing pathway.
Fig.1: Insulin receptor signal transduction via PI3K/PKB pathway. 
Insulin activates tyrosine kinase, which phosphorylates and re-
cruits different substrate adaptors such as the IRS protein fam-
ily. Tyrosine-phosphorylated IRS subsequently displays binding 
sites for numerous signaling partners, among which PI3K has a 
major role in insulin function, mainly via the activation of the 
PKB and the PKC pathways. It stimulates glucose uptake in the 
muscles via translocation of GLUT4 vesicles to the plasma mem-
brane through phosphorylation of AS160. Under basal condi-
tions, small positive GLUT4 vesicles also contain VAMP2. VAMP2 
is involved in the docking and fusion of GLUT4 vesicles with the 
plasma membrane and indeed, studies have implicated a role for 
VAMP2 in insulin-dependent trafficking in cell. 
PI3K; Phosphatidylinositol-4,5-bisphosphate 3-kinase, PKB; Pro-
tein kinase B, IRS; Insulin receptor substrate, PKC; Protein kinase 
C, GLUT4; Glucose transporter type 4, VAMP2; Vesicle-associated 
membrane protein 2, AS160; AKT substrate of 160 kDa, and INSR; 
Insulin receptor.




With regards to presence of large amount of the 
total insulin mediating glucose uptake, this exper-
imental study was conducted on the C2C12 cell 
line obtained from skeletal muscle, as one of the 
major insulin target tissues (24).
C2C12 myoblasts line (obtained from Stem 
Cells Technology Research Center, Tehran, Iran) 
were cultured in growth medium (GM) composed 
of Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco, UK), 10% fetal bovine serum (FBS, Gibco, 
UK), penicillin 100 IU/ml and streptomycin 100 
μg/ml (Gibco, UK) followed by incubation at 37˚C 
and 5% CO2, before starting differentiation pro-
cess. Upon reaching cell density to 70%, they were 
digested with 0.25% trypsin and seeded into cul-
ture dishes. As soon as obtaining more than 90% 
confluent dish, C2C12 myoblast cells differentia-
tion procedure was initiated by changing GM to 
differentiation medium (DM) containing DMEM 
supplemented with 3% horse serum (Gibco, UK). 
According to previous studies, 70% confluent 
C2C12 cells were converted in differentiation me-
dium in absence of insulin sensitive cell (IN) or in 
chronic presence of 100 nM insulin (Gibco, UK) 
resistant cell (IRC) for 3 days. 
Immunocytochemistry
After inducing myogenic differentiation, the cul-
tured C2C12 cells in 12-well plates were washed 
with PBS and fixed with 4% paraformaldehyde for 
15 minutes. 0.5% Triton X-100 was used for per-
meabilization. The cells were then blocked in 2% 
goat serum (Sigma, USA) diluted in phosphate-
buffered saline (PBS). After blocking, the cells 
were incubated with anti-PAX7 or anti-myosin 
primary antibody (Sigma, USA) at 37˚C for 1-2 
hour(s). Subsequently, the cells were washed and, 
the secondary fluorescent antibodies (Ray Bio-
thech, USA) were added to the cells at 37˚C for 
1 hour. The nuclei were ultimately stained with 
DAPI (Invitrogen, USA) for 30 seconds.
Glucose uptake study 
 In this study, untreated differentiated C2C12 
cells (NCC) were incubated in DMEM culture me-
dia and considered as negative control. In contrast, 
differentiated C2C12 cells treating with 1 mM in-
sulin (Sigma, USA) DMEM culture media, during 
the glucose uptake procedure, was used as posi-
tive control. Differentiated C2C12 cells treated 
with 100 nM insulin for 72 hours or transfected 
with miR-135 during differentiation process were 
utilized as experimental cells. After treatment, a 
glucose uptake assay was performed. Cells were 
incubated for 1 hour in glucose and serum-free 
media followed by 3 hour incubation in DMEM 
containing 5 mM glucose in the presence and ab-
sence of 1 mM insulin. Based on Gallant et al. (25) 
study, after insulin exposure, 50 ml of the media 
aliquots were taken from the respective wells and 
added to 150 ml distilled water to achieve four 
times dilution. The remaining glucose in the me-
dia was quantified using the COBAS INTEGRA 
Glucose HK GEN.3 kit (Roche, Germany). A glu-
cose standard curve was constructed using glucose 
concentrations ranging between 0.25 mmol and 2 
mmol (4.5 mg/dl and 36 mg/dl), which was meas-
ured spectrophotometrically at 340 nm (data not 
shown). All standard curve concentrations were 
determined by triplicate values.
Target prediction and pathway analysis
According to a wide range literature review and 
KEGG database (www.genome.jp/kegg), we cat-
egorized a set of significantly important genes in 
insulin resistance pathway. Using Target Scan 6.2, 
miRWalk and RNAhybrid, we generated a list of 
miRNA candidates containing a seed site for the 
previously categorized genes (26-28). Those genes 
were predicted as miRNA targets by at least two of 
three prediction databases. Based on bioinformat-
ics prediction, we found that miR-135 targeted sev-
eral biological molecules, which are regulator of 
insulin signaling pathway such as Insr and Vamp2, 
as an important component of glucose transporter 
type 4 (Gut4) translocation pathway (Fig.1). 
Construction of miR-135 expression vector
To create pre-miR expression vectors, we first 
amplified a 400 bp DNA fragment covering a pre-
miR, using mouse genomic DNA as a template. 
PCR reactions were performed corresponding 
specific primers and then amplified fragment was 
cloned into a lentiviral vector (pCDH-CMVMCS- 
EF1-copGFP from System Biosciences, USA) at 
XbaI and EcoR1 sites. Partial digestions were per-
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formed in cases that there was an internal XbaI and 
EcoR1 site to obtain the DNA fragment carrying 
the pre-miR. Expression of mature miR was con-
firmed by the TaqMan real-time PCR kit (Applied 
Biosystems, USA) (29) and bidirectional sequenc-
ing (Microgene, Korea).
Transfection of miR-135
C2C12 cells were transfected immediately after 
trypsinization, while the cells were in suspension 
with the scramble or miR-135 mimic (pCDH/miR-
135) using Lipofectamine 2000 (Invitrogen, USA). 
The 70% confluent C2C12 cells were trypsinized 
and then seeded in 6-well plates in growth me-
dium. Immediately after plating the cells, while 
they were still in suspension, differentiation me-
dium was supplemented with the complexes and 
added to the cells. The cells were incubated with 
lipid-DNA complexes, while they were attached to 
the culture dish at 37˚C and 5% CO2. The complex 
medium was removed after 24 hours followed by 
adding fresh differentiation medium. Ultimately, the 
cells and respective media were collected at 72-hour 
post-transfection of the cell differentiation and sub-
jected to reverse transcriptase-polymerase chain re-
action (RT-PCR) and glucose uptake analyses.
RNA isolation and quantitative reverse tran-
scriptase-polymerase chain reaction
Total RNA was extracted from the cells using 
TRIzol (Invitrogen, USA) according to the manu-
facturer’s instruction. The quality and concentra-
tion of total RNA were subsequently estimated 
using denatured gel electrophoresis and spectro-
photometer, respectively. According to previous 
study miR could be amplified with stem-loop real-
time PCR using specific stem-loop primers (30). 
Expression level of the corresponding predicted 
mRNA targets (Insr and Vamp2) to the selected 
miR was also validated by real-time PCR using 
gene specific primers. The threshold cycle aver-
age was used for data analysis by Rotor-gene Q 
software (Corbett, Australia). Genes and related 
specific primers are presented in the Table 1. Insr 
and Vamp2 expressions were normalized against 
the expression of β-actin. Snord-6 (U6) was also 
selected as internal control for miR expression. 
All PCRs were performed in triplicates and run 
in at least 3 independent experiments. The 2−ΔΔCt 
algorithm was employed to evaluate the relative 
expression level of each gene.
Table 1: Designed specific primers for PCR assays
Primer Sequence (5´-3´) 
Reverse transcription  
miR 135a- stem-loop 5ˊGTCGTATGCAGAGCAGGGTCCGAGGTATTCGCACTGCATACGACTCACA 3ˊ
  
qRT-PCR  
miR-135a F : 5ˊCGATATGGCTTTTTATTCCTA3ˊ
R : 5ˊGAGCAGGGTCCGAGGT 3ˊ
Insr F : 5ˊAACAGATGCCACTAATCCTTC 3ˊ
 R: 5ˊGCCCTTTGAGACAATAATCC 3ˊ
Vamp2 F: 5ˊGTCACTGCCTCTGCCAAG3ˊ
 R: 5ˊGTCCACCACCTCATCCAC3ˊ
qRT-PCR; Quantitive reverse transcriptase-polymerase chain reaction.
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Comparison of quantitative reverse tran-
scriptase-polymerase chain reaction result by a 
high throughput method data
We next investigated whether the candidate 
gene expression levels obtained by quantitative 
RT- PCR (qRT-PCR) were comparable with other 
methods. To this end, the qRT-PCR results of can-
didate genes were compared with  two microarray 
data Gene Expression Omnibus (GEO) including 
muscle samples from insulin resistance individuals 
(GEO accession # GSE6798) and blood samples 
from T2D patients (GEO accession # GSE26168) 
(31, 32).
Statistical analysis
The data are presented as mean GS.E.M. To 
determine statistical significance, student’s 
t test was applied. The significance threshold 
was set at P≤0.05. All experiments were per-
formed tree times.
Results
Characterization of C2C12 differentiation
C2C12 cells were proliferated in the presence 
of serum and differentiated upon partial serum 
deprivation from myoblast cells causing their 
differentiation into myocytes. This was vali-
dated by positive Immunocytochemistry (ICC) 
result for specific skeletal marker, myosin. Us-
ing ICC technique, we also determined C2C12 
myoblast cell type expressing precursor cells 
marker, PAX7 (Fig.2).
Fig.2: Myoblast to myocyte differentiation using 3% horse serum. A-C. C2C12 myoblasts were stained with PAX and DAPI antibodies, as 
positive control of precursor cells. After that myoblasts were differentiated with DMEM medium containing 3% horse serum during 3 
days and D-F. The differentiated cells were seeded in new plate and stained with (MyHC) antibody as well as DAPI. DAPI; 4´,6-diamidino-
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In vitro studies on miR135-transfected C2C12 cells
Quantitative reverse transcriptase-polymerase chain 
reaction analysis
qRT-PCR analysis showed that miR-135 was in-
duced and had significantly altered expression pat-
tern in miR-transfected C2C12 cells compared to 
negative control cell line  scramble (miR-135 fold 
change: 1.537, P≤0.05). We have examined Vamp2 
and Insr expressions in transfected C2C12 cells, to 
identify potential markers within development of 
insulin resistance (Fig.3). Interestingly, qRT-PCR 
analysis, showed that expression level of Insr tar-
geted by miR-135 in silico, was down-regulated in 
transfected cells (Insr fold change: 0.168, P≤0.05). 
There was a significant decrease in Insr gene ex-
pression in the transfected C2C12 cells compared 
to negative control, indicating a down-regulation 
of Insr gene expression due to the miR-135 trans-
fection. In contrast to Insr expression level in 
transfected C2C12 cells, miR-135 expression level 
was up- regulate (P≤0.05), suggesting this miR is 
responsible for the decreased level of Insr. No sig-
nificant alteration was observed on the expression 
of Vamp2 (Vamp2 fold change: 1.366, P>0.05). 
Fig.3: Expression pattern of the candidate genes during miR-135 
transfection. Based on real time (qRT-PCR) results which were 
concurrent to miR-135 up-regulation in transfected cells, Insr has 
significant down-regulated profile during differentiation process 
(P≤0.05). In contrast, no significant overexpression of Vamp2 
was observed (P>0.05). Error bars indicate SEM (n=3). qRT-PCR; 
Quantitive reverse transcriptase-polymerase chain reaction.
Sustained expression of miR-135 attenuated 
glucose uptake in C2C12
Insulin was shown to provide a significant in-
crease in the amount of glucose taken up by posi-
tive control cell (PCC).
Our PCC, showed a significant increase in glu-
cose uptake in C2C12 cells (G uptake: 48 mg/dl) 
compared to the negative control (NCC, G uptake: 
32 mg/dl, P≤0.05).
Hyperinsulinemia was used to induce insulin re-
sistance in the C2C12 cells (IRC, G uptake: 7 mg/
dl). Findings showed a significant suppression of 
glucose uptake in the IRC compared to the PCC 
(Fig.4).
Transfected C2C12 (TCC) where exposed for 
72 hours to differentiation medium. Thereafter 
glucose uptake was determined. Interestingly, 
the miR-135-trasfected cells (G uptake: 9 mg/dl) 
showed a significant difference in glucose uptake 
in comparison with PCC (P≤0.05), while it was 
similar to IRC (P=0.71). 
Fig.4: Image illustrates glucose uptake in different status of 
C2C12 cells. IRC and TCC showed a reduction in G uptake com-
pared to PCC. Error bars indicate SEM (n=3).
NCC; Normal control negative, PCC; Normal control positive, IRC; 
Insulin resistance cell, and TCC; miR-135-trasfected Cell.
Evaluation of reverse transcriptase-polymerase 
chain reaction result by microarray data 
To extend the results of qRT-PCR, we used Affy-
metrix cDNA microarray row data (GEO acces-
sions # GSE6798 and GSE26168) and analyzed 
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relative transcript levels VAMP2 and INSR in 
control samples compared to insulin resistance in 
muscle and blood samples (31, 32).
Data analysis reflected similar down-regulation 
trends for INSR expression obtained from both 
microarray results; muscle samples (INSR fold 
change: 0.884, P≤0.05) and blood samples (INSR 
fold change: 0.552, P≤0.001). This was similar to 
our observation obtained from qRT-PCR analysis 
(Fig.5). On the contrary, there was an up-regula-
tion for VAMP2 expression in all three studies. 
Muscle microarray analysis showed a significant 
up-regulation for VAMP2 (VAMP2 fold change: 
1.156, P=0.036), although no significant change 
was observed for VAMP2 expression in blood 
sample (VAMP2 fold change: 3.1949, P=0.271) in 
comparison with healthy control (Fig.5).
Fig.5: Comparison of miR-135 predicted gene target expres-
sion levels during myogenesis using two different methods. Fold 
changes in qRT-PCR and two microarrays were compatible for 
INSR as well as qRT-PCR Muscle microarray for VAMP2 (P≤0.05). 
Error bars indicate SEM (n=3). qRT-PCR; Quantitive reverse tran-
scriptase-polymerase chain reaction.
Discussion
The present study investigated association of the 
miR-135 and relative targets to insulin resistance 
in vitro, with the aim to understand the processes 
involved in pathogenesis of T2D. It has been re-
ported that miRs can potentially be served as novel 
regulator of diseases, including T2D (6, 14). This 
theory was supported by Kosaka et al. (33) which 
generated the idea of miRs-mediated intercellular 
statement. Although there are several reports de-
scribing the status and role of miRs in diabetic tis-
sues, very few studies have focused on the diabetic 
skeletal muscle (7, 8, 17, 18, 34).
The principal objective of present study was 
based on the fact that defects in the insulin signal-
ing pathway leads to T2D and insulin resistance 
is crucial stage on the onset of this disease. Based 
on our comprehensive integrative bioinformat-
ics analysis, several pathways intermediate a role 
in T2D development, including insulin signaling 
pathway. Along with all those candidates, miR-
135 and the relative targets, especially Insr, are 
among the original top-ranking T2D risk factors. 
Our data showed that Insr gene expression was 
significantly down-regulated in C2C12 cells after 
transfection with miR-135. Increased expression 
of the miR-135 had accompanied with decline in 
the expression of Insr, as the first component of the 
insulin signaling pathway, compared to the control 
cell line. However, Vamp2 was not significantly 
changed after transfection with miR-135. Since 
we had observed an inverse expression pattern of 
miR-135 and Insr in the transfected C2C12 cells, 
our team sought to identify whether it has any ef-
fect on glucose uptake. Interestingly, the miR-135 
transfected cells showed a down-regulation of Insr 
gene expression accompanied with a significant 
decrease in glucose uptake when compared to 
PCC, while it was the same as IRC. We determined 
that reduction of Insr expression level in the pres-
ence of miR-135, contributed to the downstream 
effects of insulin action. INSR is a critical compo-
nent of the insulin signaling cascade .Therefore, 
abnormality of INSR expression appears to be a 
significant defect that may result in reduction of 
insulin-stimulated glucose disposal in muscle. To 
confirm our results, we compared them with Affy-
metrix cDNA microarray data obtained from GEO 
accession numbers GSE6798 and GSE26168. 
Skov et al. (31) had previously analyzed 13 dif-
ferent RNA samples from healthy control and  16 
different RNA samples from obese human insulin 
resistance vastus lateralis muscle (overall 29 mi-
croarrays, GEO accession # GSE6798). These in-
dividuals were selected from a larger cohort who 
participated in a previously reported study. In the 
other study, Karolina et al. (32), carried out mRNA 
microarray investigation on 8 different peripheral 
blood RNA samples of T2D individuals and 9 con-
trol samples (GEO accession # GSE26168). Mi-
croarray analysis confirmed our findings (P≤0.05) 
except for VAMP2. However, the magnitude of 
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microarray data changes was not similar to qRT-
PCR results. Regarding that qRT-PCR indicator 
is linear over a wide concentration series (35), 
as completed by serial dilution tests with differ-
ent samples (data not shown), we believe that this 
technique provides a more accurate representation 
of changes in the level of specific transcripts in 
the miR-135 transfected versus the normal C2C12 
cells, compared to the microarray analysis. Never 
the less, both studies indicated that there is a signif-
icant down-regulation of INSR expression pattern 
in insulin resistance and T2D samples.
According to our main results, miR-135 over-
expression has negative effects on glucose up-
take seemingly through targeting Insr in the 
insulin signaling pathway. It gives the impres-
sions that overexpression of miR-135 could be 
involved in insulin resistance, and it could affect 
related pathways responding normally to insulin 
using signaling molecules involved in removing 
glucose in tissues, through down-regulation of 
Insr. Consistent with our finding, Agarwal et al. 
(36) found that miR-135 level was elevated in 
diabetic skeletal muscle and miR-135 silence 
in vivo improved glucose tolerance via down-
regulation of IRS2, the other member of insu-
lin signaling cascade. Targeting different com-
ponents of one signaling pathway by a single 
miR implicates the regulatory role of respective 
miR (37, 38). Hence, our results accompanied 
with Agawal’s finding further confirming the in-
volvement of miR-135 in insulin resistance.
Conclusion
In this study, it was demonstrated that the lack 
of Insr expression and increased level of miR-135, 
contributed to the poor stimulation of glucose up-
take by insulin in C2C12 cell line developing insu-
lin resistance phenotype. However, further studies 
are required to address complex regulatory roles 
of this miR. Establishing the role and regulation 
of muscle miRs will enhance our understanding 
about insulin resistance development. Combining 
informatics, biochemical and genetic approaches 
not only will lucid the miR regulatory role in T2D, 
but also will raise new opportunities for therapeu-
tic intervention in this complex diseases by identi-
fying candidate miRs as potential targets for clini-
cal application.
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